Engagements
Choose the review that matches the delayed decision.
One review is for pharma teams carrying a stalled access or launch question. The
other is for risk-bearing operators carrying a stalled protocol or pathway decision.
Pharma teams
Access and launch review
For launch, market access, HEOR, medical, and brand teams dealing with one access
or account-movement problem around a therapy class, patient segment, or account.
- Use it when the commercial drag is already visible.
- You get a written assessment of the issue, the decision path, and the next step.
- Best for one concrete problem, not a portfolio sweep.
Risk-bearing operators
Protocol and pathway review
For CMOs, governance leads, and risk-bearing operators dealing with one pathway or
protocol decision that has stalled.
- Use it when waiting is already affecting cost, quality, or operations.
- You get a written assessment of whether the change is ready, who must approve it, and what to do next.
- Best for one concrete decision before broader implementation work.
Contact
If you can already name the stalled decision, send a short note.
Keep the first note short: problem, stake, owner, and bottleneck.